iBioIBIO
IBIO
About: iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Employees: 16
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
11% more funds holding
Funds holding: 28 [Q2] → 31 (+3) [Q3]
2% more capital invested
Capital invested by funds: $5.68M [Q2] → $5.79M (+$106K) [Q3]
1.06% less ownership
Funds ownership: 31.23% [Q2] → 30.17% (-1.06%) [Q3]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$6
97%
upside
Avg. target
$6
97%
upside
High target
$6
97%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
LUCID CAPITAL MARKETS Dev Prasad 67% 1-year accuracy 2 / 3 met price target | 97%upside $6 | Buy Initiated | 17 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Regain, Potentially Enabling Less Frequent Dosing than Current Obesity Treatments Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Regain, Potentially Enabling Less Frequent Dosing than Current Obesity Treatments
Neutral
GlobeNewsWire
2 months ago
iBio Reports Fiscal First Quarter 2025 Financial Results
Advanced myostatin program with dosing underway in non-human primate study Advanced myostatin program with dosing underway in non-human primate study
Neutral
GlobeNewsWire
4 months ago
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
4 months ago
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.
Neutral
GlobeNewsWire
5 months ago
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets
Neutral
GlobeNewsWire
7 months ago
iBio Closes Sale of Manufacturing Facility in Texas
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, has met all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property.
Neutral
GlobeNewsWire
8 months ago
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.
Negative
InvestorPlace
9 months ago
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.
Positive
Invezz
9 months ago
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
Positive
Proactive Investors
9 months ago
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.
Charts implemented using Lightweight Charts™